CIBC World Market’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2M Sell
218,677
-15,996
-7% -$114K ﹤0.01% 884
2026
Q2
$1.54M Buy
234,673
+83,723
+55% +$577K ﹤0.01% 920
2026
Q1
$1.09M Buy
150,950
+92,900
+160% +$748K ﹤0.01% 911
2025
Q4
$437K Buy
58,050
+43,050
+287% +$265K ﹤0.01% 1164
2025
Q3
$88.4K Hold
15,000
– – ﹤0.01% 1377
2025
Q2
$86.4K Buy
+15,000
New +$57.6K ﹤0.01% 1321

Other funds holding EPRX

CIBC World Market's EPRX Position: Q3 2026 in Review

CIBC World Market reduced its Eupraxia Pharmaceuticals (EPRX) stake by 6.8% in Q3 2026, selling an estimated $114K and leaving 218,677 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #884.

CIBC World Market first reported a position in EPRX in Q2 2025 and has held it in 6 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • CIBC World Market held 218,677 shares of Eupraxia Pharmaceuticals worth $2M as of Q3 2026.
  • CIBC World Market sold 15,996 Eupraxia Pharmaceuticals shares in Q3 2026, an estimated $114K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of CIBC World Market's portfolio in Q3 2026, its #884 holding.
  • CIBC World Market first reported a position in Eupraxia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on CIBC World Market's 13F filing for Q3 2026, filed 10 Nov 2026.